Metabolomics Moving Towards A Better Understanding of Desmoid Tumors

Size: px
Start display at page:

Download "Metabolomics Moving Towards A Better Understanding of Desmoid Tumors"

Transcription

1 Metabolomics Moving Towards A Better Understanding of Desmoid Tumors Kelly Mercier, Ph.D NIH Eastern Regional Comprehensive Metabolomics Resource Core at RTI International RTI International is a registered trademark and a trade name of Research Triangle Institute.

2 What Is RTI International? RTI is an independent, nonprofit institute that provides research, development, and technical services to government and commercial clients worldwide. Our mission is to improve the human condition by turning knowledge into practice.

3 Notable Achievements Taxol and camptothecin Speech processing for cochlear implants Survey technology (ACASI) Wind shear avoidance system Indoor air quality research Neglected tropical disease control Clean coal technology Malaria, HIV, and tuberculosis prevention and treatment programs

4 Metabolomics Metabolomics involves the analysis of the low molecular weight complement of cells, tissues, or biological fluids. Metabolomics makes it feasible to uniquely profile the biochemistry of an individual or system. Metabonomics is used to determine the pattern of changes (and related metabolites) arising from disease, dysfunction, disorder, or from the therapeutic or adverse effects of xenobiotics Mammalian, plant, and aquatic species This leading-edge method has come to the fore to reveal biomarkers for the early detection and diagnosis of disease, to monitor therapeutic treatments, and to provide insights into biological mechanisms.

5 NIH Common Fund Metabolomics Cores NIH Metabolomics Centers Ramp Up November 4, 2013 Issue - Vol. 91 Issue 44 Chemical & Engineering News. by Jyllian Kemsley

6 Research Collaborations Investigational Areas Treatment Intervention Nutrition Fat, Soy, Casein, Rice Exposure Metals, PAHs, Wood Smoke, PM2.5 Mental Health Schizophrenia, Bipolar Disorder, Anxiety Development Reproduction Cancer Climate Change Barth Syndrome Infection Opthamology Sample Types Kidney Liver Brain Ovary Eye Lung Muscle Serum Plasma Feces Urine Saliva Mussel Rice Sample Origin Humans Elderly Adults Children Neonates Pregnancy Animal models Primates Rodents Aquatic Insects Cells

7 Women s and Children s Health Pediatric Glomerular Disease Bill Smoyer Neonatal Acute Kidney Injury Pat Brophy David Askenazi Barth Syndrome Hilary Vernon Arsenic, in utero exposure, diabetes Rebecca Fry PAH, in utero exposure, birth outcomes, MDI Fredrica Perea Pregnancy Complications Michelle Williams Phthalates and Pediatric Obesity Leo Transnade New award Childhood Infections Margaret Karagas New award Pediatric Obesity David Collier in utero exposure, obesity Catherine Hoyo

8 Desmoid Tumor Cell Lines Dr. Ben Alman (Duke University) and the Desmoid Collaboration for a Cure Dr. Ben Alman Desmoid Collaboration for a Cure Progress: Screened 9 primary cell lines 5 different compound libraries 45 compounds inhibited cell proliferation in desmoid tumors by greater than 50% with no effect on normal fibroblast proliferation All either approved for use in patients or have the potential to be rapidly developed for patient care. Mushriq Al- Jazrawe RTI has initiated a collaboration with Dr. Alman and his group

9 Metabolomics Meets Desmoid Tumors Novel Therapeutics Use broad spectrum and targeted metabolomics to investigate how the cell lines respond to efficacious drugs identified by the Desmoid Collaboration for a Cure What effects are different for each desmoid-normal fibrobast pair for all drugs? What effects are the same for each desmoid-normal fibrobast pair for all drugs?

10 Metabolomics Meets Desmoid Tumors Basic Biology Use broad spectrum and targeted metabolomics to investigate: Primary desmoid tumor cell lines Matched normal fibroblast cell lines Unaffected fibroblast cell line What biochemical processes differentiate the matched desmoid tumors from the adjacent fibroblast? What biochemical differences are there between the matched fibrobasts and the unaffected?

11 Metabolomics Meets Desmoid Tumors Recurrence and Prediction Biomarkers Use broad spectrum and targeted metabolomics to investigate tissue or cells associated with a primary dissections verse N+1 dissections What metabolites define the primary mass verses the N+1? Can metabolites be found that predict likelihood of regrowth? Use broad spectrum and targeted metabolomics to predict response to treatment Partner with a clinician running a clinical trial Identify patients that are high responders and low responders

12 1 H NMR Spectrum of Primary Cell Line 233 RTI RCMRC Preliminary Data Glycine Carnitine Glutamate Glutamine Lactate Threonine myo-inositol Alanine Creatine phosphate Lactate Glucose Threonine Creatine Creatinine Methionine N-acetyl amino acids Arginine Lysine BCAA

13 1 H NMR Spectrum of Primary Cell Line 233 and 235 RTI RCMRC Preliminary Data Media from Primary Cell Line 233 Media from Primary Cell Line 235 Blank Media Lactate Succinate Pyruvate BCAA Glutamate Alanine Propylene Glycol 3-HBA 3-Methyl-2- oxovalerate

14 Metabolomics and Barth Syndrome Rare disease characterized by dilated cardiomyopathy skeletal myopathy neutropenia short stature Transmitted from mother to son as an X-linked genetic condition as mutation of the tafazzin (TAZ or G4.5) A RTI RCMRC Pilot and Feasibility Study: NMR and LC-MS analysis of plasma Further define metabolic and molecular pathways involved in metabolism Identify potential targets for treatment 23 Barth Syndrome patients and 11 age-matched controls Dr. Hilary Vernon Johns Hopkins U. Dr. Yana Sandlers Cleveland State U.

15 NMR and LC-MS of plasma from Barth Syndrome Cases and Healthy Subjects NMR NMR Library Matched Bins VIP p-value* 3-Hydroxybutyrate Carnitine, Lipids/Fatty Acids Creatinine, Overlap Lipids/Fatty Acids (4) Methionine Proline, Lipids/Fatty Acids Unsaturated Lipids/Fatty Acids (2) VLDLs VLDLs, Unknown LC-MS Biocrates p180 assay Acyclcarnitines, Amino acids, Biogenic amines, and Glycerophospholipids all differentiated the Barth Syndrome patients from the controls. Control- Case-

16 Metabolomics and Target Identification Distribution of Biochemical Functions

17 RTI - RCMRC Susan Sumner Center Director Wimal Pathmasiri NMR & GC-MS Tim Fennell In vivo Metabolism Susan McRitchie Data Analysis Zach Acuff Biostatistics Bob Clark Genetics Jocelin Spruill GC-MS Jim Carlson LC- and GC-MS Jessica Gooding LC-MS Andrew Novokhatny Quality Control Tammy Cavallo Quality Control Ninell Mortensen Microbiology Kelly Mercier NMR Jason Burgess NMR Rod Snyder LC-MS Delisha Stewart Cell Biology Keith Levine Metallomics James Harrington Metallomics

18 Funding NIDDK: NIH Common Fund 1U24DK097193: NIDDK: Sumner, RTI, PI NIH Eastern Regional Comprehensive Metabolomics Resource Core NIEHS U2C ES : Timothy Fennell, PI Children s Health Exposure Analysis Resource (CHEAR) Hub NIGMS: NIH Common Fund 5R25GM103802: Martin Kohlmeier, UNC-CH, PI Online learning platform introducing clinicians and researchers to metabolomics. NEI: NIH Common Fund R01EY012224: Ellen Weiss, UNC-CH, PI Desensitization of Cone Visualization Signaling Pathways. NHLBI: NIH Common Fund HHSN C:Herb Seltzman, PI; Metabolite Standards Synthesis Core NIDDK: 1UMDK : PI s: William Smoyer, Nationwide Children s Hospital & Larry Greenbaum, Emory. Integrated Proteomics and Metabolomics for Pediatric Glomerular Disease NIEHS: U19ES year 5: PI: Timothy Fennell Estimating Human Health Risks from Exposure to Nanoparticles NCATS: UL1TR00111: PI: John Buse (UNC-CH), North Carolina Translational and Clinical Sciences Institute- NCTraCS

Wimal Pathmasiri, Rodney Snyder NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC)

Wimal Pathmasiri, Rodney Snyder NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC) NMR Hands On UAB Metabolomics Training Course July 17-21, 2016 Wimal Pathmasiri, Rodney Snyder NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC) is a trade name of Research Triangle

More information

NMR Data Pre-processing

NMR Data Pre-processing NMR Data Pre-processing UAB Metabolomics Training Course July 17-21, 2017 Wimal Pathmasiri and Delisha Stewart NIH Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC) Department of Nutrition

More information

NMR Data Analysis Exercise

NMR Data Analysis Exercise NMR Data Analysis Exercise UAB Metabolomics Training Course July 17-21, 2017 Wimal Pathmasiri and Delisha Stewart NIH Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC) Department of Nutrition

More information

Metabolomics to Provide Biomarkers and Mechanistic Insights

Metabolomics to Provide Biomarkers and Mechanistic Insights Metabolomics to Provide Biomarkers and Mechanistic Insights Susan Sumner, PhD Director NIH Eastern Regional Comprehensive Metabolomics Resource Core Systems and Translational Sciences Program ssumner@rti.org

More information

Stealth BioTherapeutics Mission:

Stealth BioTherapeutics Mission: The following is a summary of a live presentation offered through joint collaboration with UMDF, MitoAction and the Foundation for Mitochondrial Medicine to the mitochondrial disease patient and family

More information

Organs on Chips: The Future of Translational Research

Organs on Chips: The Future of Translational Research Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug

More information

NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts)

NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts) NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts) 1. NCI (National Cancer Institute) cancer cause, prevention, detection, diagnosis, treatment and control 2. NIAID

More information

Metabolomics S.M.Shotorbani, V. A. Suliman

Metabolomics S.M.Shotorbani, V. A. Suliman 13 International Journal of Advance Research, IJOAR.org Volume 1, Issue 1, January 2013, Online: Metabolomics S.M.Shotorbani, V. A. Suliman ABSTRACT A brief review on metabolomics, a new field being explored,

More information

Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice

Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice Mattias Rantalainen, Olivier Cloarec, Olaf Beckonert, I. D. Wilson, David Jackson, Robert Tonge,

More information

Metabolomics to Provide Biomarkers and Mechanistic Insights

Metabolomics to Provide Biomarkers and Mechanistic Insights Metabolomics to Provide Biomarkers and Mechanistic Insights Susan Sumner, PhD Director NIH Eastern Regional Comprehensive Metabolomics Resource Core Systems and Translational Sciences Program RTI International

More information

Metabolomics: Techniques and Applications ABRF

Metabolomics: Techniques and Applications ABRF Metabolomics: Techniques and Applications ABRF Sacramento, CA March 23, 2010 Overview Metabolomics Definitions Representative Project Sarcosine, a prostatic cancer biomarker Technical overview/ How we

More information

What is the Future of NIH funded Clinical Research in IBD?

What is the Future of NIH funded Clinical Research in IBD? IBD Clinical Trials Workshop What is the Future of NIH funded Clinical Research in IBD? Stephen P. James, M.D. January 13-14, 2017 Future? FY 2015 NIH Awards for IBD related research 338 Awards $128 Million

More information

North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA)

North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA) North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA) What is Translational Research? Translational research includes

More information

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTES OF HEALTH (dollars in millions) 2011 2012 2013 2013 +/- 2012 Institutes National Cancer Institute... 5,050 5,066 5,069 +3 National Heart, Lung and Blood Institute... 3,065 3,075 3,076

More information

LETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department

LETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department Adrienne Pervès adrienne.perves@cea.fr Deputy Director LETI Technologies for Biology and healthcare Department LETI-HEALTH Micro- NanoTechnologies for Healthcare and Biology MISSION AND EXPERTISE Focused

More information

Analyzing and utilizing NIH award data Perry Kirkham, Ph.D.

Analyzing and utilizing NIH award data Perry Kirkham, Ph.D. Analyzing and utilizing NIH award data Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 What decisions can be informed through the use of NIH data?

More information

What IMI means for POLAND

What IMI means for POLAND What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)

More information

Technology Development Funding Program Round 3

Technology Development Funding Program Round 3 Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science

More information

Antibody Discovery at Evotec

Antibody Discovery at Evotec Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic

More information

ENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS. Torbjörn Lundstedt Professor in Chemometrics C.S.O.

ENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS. Torbjörn Lundstedt Professor in Chemometrics C.S.O. A cure o m i c s ENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS Torbjörn Lundstedt Professor in Chemometrics C.S.O. AcureOmics AB Thessaloniki, Greece, 19 th of May, 2016 1

More information

Government Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER

Government Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER www.g2gconsulting.com Government Bioscience Grant (GBG) Report October 2016 Title (Agency) Opp. Number Description Deadline Funding Level Eligibility Link BROAD AGENCY ANNOUNCEMENTS 1. Advanced Research

More information

leading the way in research & development

leading the way in research & development leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and

More information

New test for transplant rejection on the horizon

New test for transplant rejection on the horizon December 6, 2004 New test for transplant rejection on the horizon Vancouver Researchers at St. Paul s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate

More information

The Five Key Elements of a Successful Metabolomics Study

The Five Key Elements of a Successful Metabolomics Study The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and

More information

FP7 Cooperation Work Programme: Health-2011 Topics and contact points

FP7 Cooperation Work Programme: Health-2011 Topics and contact points FP7 Cooperation Work Programme: Health-2011 Topics and contact points Date of publication: 30 July 2010 Call identifiers: Indicative budgets Deadlines FP7-HEALTH-2011-single-stage EUR 160.5 million 10

More information

IGPNS Recommended Electives List

IGPNS Recommended Electives List IGPNS Recommended Electives List Animal Science 414: Ruminant Nutrition Integrates basic nutrition concepts and ration balancing skills by teaching students to balance and troubleshoot rations for various

More information

NIMH Updates and Research Priorities

NIMH Updates and Research Priorities NIMH Updates and Research Priorities ASCP Annual Meeting May 31, 2018 Shelli Avenevoli, Ph.D. Disclosure of Affiliations No conflicts of interest or disclosures 2 Agenda NIH and NIMH Updates NIMH Intervention

More information

Our website:

Our website: Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate

More information

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices

More information

Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013

Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic

More information

The National Institutes of Health ICs: mission and funding strategies

The National Institutes of Health ICs: mission and funding strategies The National Institutes of Health ICs: mission and funding strategies Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 NIH Workshop topics and dates

More information

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA

More information

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration

More information

Clinical Trials Development Resource for Hematologic Disorders (U24)

Clinical Trials Development Resource for Hematologic Disorders (U24) Clinical Trials Development Resource for Hematologic Disorders (U24) Diane Catellier, DrPH RTI International RTI International is a trade name of Research Triangle Institute. www.rti.org What is the U24

More information

Metabolomics. A GlobalMarketOverview. TechnologiesandApplications. ReportCode:BT004 Pages:508 Charts:306 Price:Sample

Metabolomics. A GlobalMarketOverview. TechnologiesandApplications. ReportCode:BT004 Pages:508 Charts:306 Price:Sample I I Biotechnology Metabolomics TechnologiesandApplications A GlobalMarketOverview Thereportreviews,analyzesandprojects theglobalmarketformetabolomictechnologies andapplicationsfortheperiod2010-2020. Published:Nov2014

More information

METABOLIC PROFILING AND SIGNATURES IN ALS. Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina

METABOLIC PROFILING AND SIGNATURES IN ALS. Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina METABOLIC PROFILING AND SIGNATURES IN ALS Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina Metabolomics is the newest Omics science DNA Genomics RNA Transcriptomics

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

BIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus

BIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus Course Director: BIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus Location and meeting times Mo/We 10:30am 11:50am, George Auditorium Martin Tenniswood, PhD Department of Biomedical Sciences

More information

Disruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health

Disruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health Disruptive Innovation at the NIH Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health NIH: Steward of Medical and Behavioral Research for the Nation Science in

More information

PATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE

PATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE PATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE CHRISTOPHER LEPTAK, M.D., PH.D. DIRECTOR, OND REGULATORY SCIENCE PROGRAM CO-DIRECTOR, BIOMARKER QUALIFICATION PROGRAM NASH Biomarkers Workshop May 5,

More information

Request for Projects for Wake Forest Brain Tumor SPORE Application

Request for Projects for Wake Forest Brain Tumor SPORE Application 1 Request for Projects for Wake Forest Brain Tumor SPORE Application This RFA is for three types of projects that will be taken into consideration for inclusion in the Wake Forest Brain Tumor Specialized

More information

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells

More information

National Institutes of Health 101

National Institutes of Health 101 National Institutes of Health 101 Perry Kirkham, Ph.D. Office of the Executive Vice President for Research and Partnerships E-mail: pkirkham@purdue.edu Phone: 63645 Questions and topics to be addressed

More information

Newborn Screening Policy Development in the United States

Newborn Screening Policy Development in the United States Newborn Screening Policy Development in the United States The Changing Scene and The Way Forward in the Genomic Era Association of Public Health Laboratories 2013 Annual Meeting Raleigh, North Carolina

More information

The Power to Cure: Therapeutic Innovation in Academia

The Power to Cure: Therapeutic Innovation in Academia The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La

More information

NIH-RAID: A ROADMAP Program

NIH-RAID: A ROADMAP Program NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the

More information

Capabilities & Services

Capabilities & Services Capabilities & Services Accelerating Research & Development Table of Contents Introduction to DHMRI 3 Services and Capabilites: Genomics 4 Proteomics & Protein Characterization 5 Metabolomics 6 In Vitro

More information

Exposome: Challenges and Opportunities in the study of NCDs

Exposome: Challenges and Opportunities in the study of NCDs Imperial College London Exposome: Challenges and Opportunities in the study of NCDs Paul Elliott Imperial College London School of Public Health Disclosures (Paul Elliott) Dr Elliott receives funding from

More information

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts January 11, 2019 Table of Contents (TOC) Web Version

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts January 11, 2019 Table of Contents (TOC) Web Version Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts January 11, 2019 Table of Contents (TOC) Web Version Notices Notice of Information: Updates and clarifications of several

More information

Introduction to Basic Human Genetics. Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland

Introduction to Basic Human Genetics. Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Introduction to Basic Human Genetics Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and Reproductive Health Research Geneva

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

Stem Cells: Introduction and Prospects in Regenerative Medicine.

Stem Cells: Introduction and Prospects in Regenerative Medicine. Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,

More information

Part 1 examination. Clinical Biochemistry: First paper. Tuesday 26 September Candidates must answer FOUR questions only

Part 1 examination. Clinical Biochemistry: First paper. Tuesday 26 September Candidates must answer FOUR questions only Tuesday 26 September 2017 Candidates must answer FOUR questions only Time allowed: three hours 1. Outline how pre-analytical factors can affect the results of clinical biochemistry tests and describe what

More information

Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts

Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration

More information

Proteomics and Metabolomics in Psychiatry

Proteomics and Metabolomics in Psychiatry Proteomics and Metabolomics in Psychiatry Advances in Biological Psychiatry Vol. 29 Series Editors W.P. Kaschka Ravensburg W.F. Gattaz São Paulo Proteomics and Metabolomics in Psychiatry Volume Editor

More information

Patient Focused Drug Development 2.0

Patient Focused Drug Development 2.0 Patient Focused Drug Development 2.0 September 15, 2015 Pat Furlong, PPMD ParentProjectMD.org Understanding the Duchenne Muscular Dystrophy Environment 2 About Duchenne muscular dystrophy X-linked, pediatric

More information

All research lines at the LMU have a strong methodological focus

All research lines at the LMU have a strong methodological focus Content: Genetic Epidemiology and Statistical Genetics in Complex Diseases... 2 Molecular Epidemiology of Complex Phenotypes... 2 Clinical Trials and Translational Medicine... 3 Clinical Epidemiology and

More information

Four new Gillings Innovation Labs awarded

Four new Gillings Innovation Labs awarded Four new Gillings Innovation Labs awarded February 25, 2016 Four teams of researchers at the UNC Gillings School of Global Public Health have been awarded new funding for Gillings Innovation Labs (GILs),

More information

Understanding brain diseases from stem cells to clinical trials

Understanding brain diseases from stem cells to clinical trials Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic

More information

Personalized. Health in Canada

Personalized. Health in Canada Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute

More information

MRC-NIHR National Phenome Centre

MRC-NIHR National Phenome Centre MRC-NIHR National Phenome Centre PROFESSOR JEREMY NICHOLSON Director of the MRC-NIHR National Phenome Centre OUR PHILOSOPHY Disease risk at the individual and population level is determined by complex

More information

How Targets Are Chosen. Chris Wayman 12 th April 2012

How Targets Are Chosen. Chris Wayman 12 th April 2012 How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench

More information

Personalised Medicine Regulatory Issues

Personalised Medicine Regulatory Issues Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy

More information

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the

More information

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes

More information

Opportunities for industry/smes in EU-funded health research

Opportunities for industry/smes in EU-funded health research Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005

More information

Genomics Changing the Way Care is Delivered

Genomics Changing the Way Care is Delivered Genomics Changing the Way Care is Delivered Eric P. Hoffman, PhD Director, Center for Genetic Medicine Research A. James Clark Professor of Molecular Genetics Children s National Medical Center Washington,

More information

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established

More information

Rare Diseases: Challenges and Opportunities NIH Perspective

Rare Diseases: Challenges and Opportunities NIH Perspective Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes

More information

Page 1 of 5 Message from the Director: As the summer kicks off, many of us will renew our focus on research and scholarship. Towards this goal, we draw your attention to a several upcoming events and opportunities

More information

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary

More information

The Role of the NIH Clinical Center in Translational and Clinical Research

The Role of the NIH Clinical Center in Translational and Clinical Research The Role of the NIH Clinical Center in Translational and Clinical Research International Conference on Engineering Science and Technology 2014 John I. Gallin, M.D. Director, NIH Clinical Center Associate

More information

Asterand Bioscience Strategic Alliances

Asterand Bioscience Strategic Alliances Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in

More information

Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process

Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Petra Kaufmann, MD, MSc, FAAN Director, Division of Clinical Innovation NCATS/NIH DIA MEETING, WASHINGTON

More information

6th Form Open Day 15th July 2015

6th Form Open Day 15th July 2015 6th Form Open Day 15 th July 2015 DNA is like a computer program but far, far more advanced than any software ever created. Bill Gates Welcome to the Open Day event at the Institute of Genetic Medicine

More information

Overview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014

Overview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014 Genetics where is it leading us? Jill Goldman, MS, MPhil, CGC Taub Institute Columbia University Medical Center Overview Why are there so many research studies on the genetics of? How much of is genetic?

More information

Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks

Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks September 5, 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II

More information

The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC

The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator

CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:

More information

Clinical and Translational Science Award (CTSA) program director/principal investigator

Clinical and Translational Science Award (CTSA) program director/principal investigator Splemental digital content for Kost RG, Leinberger-Jabari A, Evering TH, et al. Helping basic scientists engage with community Splemental Digital Appendix 1 Organizational Chart for Community-Engaged Research

More information

Metabolomics. Primary Molecules. Secondary Molecules TMAO. creatinine citrate. hippurate. allantoin creatinine taurine. urea water.

Metabolomics. Primary Molecules. Secondary Molecules TMAO. creatinine citrate. hippurate. allantoin creatinine taurine. urea water. Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (22) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

Biomolecular Characterization for Rational Drug Design. Maria João Romão

Biomolecular Characterization for Rational Drug Design. Maria João Romão Biomolecular Characterization for Rational Drug Design Maria João Romão UCIBIO@REQUIMTE Applied Molecular Biosciences Unit Chemistry Department - FCT NOVA mjr@fct.unl.pt / http://sites.fct.unl.pt/xtal

More information

Nature Reviews: Drug Discovery Nicholson et al. (2002)

Nature Reviews: Drug Discovery Nicholson et al. (2002) Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (2002) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Incorporating New TB Diagnostics into RePORT

Incorporating New TB Diagnostics into RePORT Incorporating New TB Diagnostics into RePORT Susan Dorman Johns Hopkins University School of Medicine REPORT MEETING, DURBAN, JULY 2016 MACS designed to: 1. Elucidate the natural history of the infection

More information

DBT Embarks on Pre-term Birth Program

DBT Embarks on Pre-term Birth Program DBT Embarks on Pre-term Birth Program Preamble: Program on pre-term birth is the first inter-institutional program on maternal-infant health and spontaneous pre-term birth sciences in India funded by the

More information

Submission Limitations: Emory University may submit only 1 application for this program

Submission Limitations: Emory University may submit only 1 application for this program National Institutes of Health NIAMS Rheumatic Diseases Research Core Centers (P30) Website: http://grants.nih.gov/grants/guide/rfa-files/rfa-ar-12-002.html Agency Deadline: February 1, 2012 (Letters of

More information

Up Close and Personal

Up Close and Personal Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent

More information

About ICarbonX. Learn more:

About ICarbonX. Learn more: About ICarbonX icarbonx is a technology company, combining advances in artificial intelligence, multi-omics and experience to fundamentally change how people understand their present to optimize their

More information

BIOCRATES Life Sciences AG Short Company Presentation

BIOCRATES Life Sciences AG Short Company Presentation BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life

More information

ANIMAL BEHAVIOR CORE - We need your input!!!

ANIMAL BEHAVIOR CORE - We need your input!!! Page 1 of 5 Message from the Director April tends to be a busy month for all; students and faculty are preparing for the end of the semester. The Integrative Neuroscience Center Leadership Team has started

More information

Nature Reviews: Drug Discovery Nicholson et al. (2002)

Nature Reviews: Drug Discovery Nicholson et al. (2002) Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (2002) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine

More information

CTSA collaborators. Planning Pilot Studies in. Science. The origin of this talk. Summary. Charity G. Moore, PhD, MSPH July 7, 2011

CTSA collaborators. Planning Pilot Studies in. Science. The origin of this talk. Summary. Charity G. Moore, PhD, MSPH July 7, 2011 Planning Pilot Studies in Clinical and Translational Science CTSA collaborators Rickey E. Carter (Mayo) Paul lnietert t (MUSC) Paul Stewart (UNC) Charity G. Moore, PhD, MSPH July 7, 2011 The origin of

More information

A bold vision for 2025

A bold vision for 2025 Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015

More information

Competing & Collaborating to Achieve Successful Drug Repositioning

Competing & Collaborating to Achieve Successful Drug Repositioning Competing & Collaborating to Achieve Successful Drug Repositioning Noel Southall, Ph.D. National Human Genome Research Institute National Institutes of Health July 14, 2011 NIH Chemical Genomics Center

More information

Small Interfering RNA s Molecular biology and use in therapy

Small Interfering RNA s Molecular biology and use in therapy Small Interfering RNA s Molecular biology and use in therapy Dr Stuart Hamilton - NHMRC Early Career Fellow Serology and Virology Division, SEALS Microbiology, Prince of Wales Hospital; School of Women

More information

PMHDC Principal Investigators:

PMHDC Principal Investigators: OVERVIEW Precision Medicine (PM) is an approach to disease detection, prevention, and treatment based on people s individual differences. The Precision Medicine and Health Disparities Collaborative (PMHDC,

More information

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines

More information